CLRB•benzinga•
What's Behind Cellectar Biosciences' Stock Surge? FDA Update Explained
Summary
Cellectar's Iopofosine I 131 earned FDA breakthrough therapy designation for relapsed Waldenstrom macroglobulinemia following strong trial data.
Original Article
Read the full article from the original source for complete details and context.
Read Full ArticleArticle published on June 4, 2025 by benzinga